Minerva Neurosciences to Host Key Opinion Leader Meeting on Avolition, the Most Central Domain for the Successful Treatment o...
29 February 2020 - 12:30AM
Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage
biopharmaceutical company focused on the development of innovative
therapies to treat unmet medical needs of central nervous system
(CNS) disorders, today announced that it will host a Key Opinion
Leader (KOL) breakfast to discuss the importance of improving
avolition in the successful treatment of negative symptoms of
schizophrenia on Friday, March 6, 2020 in New York.
The event will be hosted by Dr. Remy Luthringer, Executive
Chairman and Chief Executive Officer of Minerva, and will feature a
brief presentation and moderated discussion with Philip Harvey,
PhD, from the University of Miami Miller School of Medicine, and
Greg Strauss, PhD, from the Georgia Psychiatric Risk Evaluation
Program. They will discuss Dr. Strauss’s paper on the central role
of avolition, defined as reductions in the desire for and
initiation of motivated behavior, in treating negative symptoms in
schizophrenia that was published recently in Schizophrenia
Bulletin. A Q&A session will be held at the conclusion of the
event.
Dr. Strauss will discuss his findings in the context of data
from the Phase 2b study of Minerva’s lead product candidate,
Roluperidone (MIN-101), a novel 5-HT2A and σ₂ receptor antagonist.
Roluperidone is currently in a pivotal Phase 3 clinical trial for
the treatment of negative symptoms of schizophrenia.
Greg Strauss, PhD directs the Clinical Affective Neuroscience
Laboratory and Georgia Psychiatric Risk Evaluation Program
(G-PREP). He has authored over 120 publications, and his research
has been recognized by several awards, such as the Early Career
Award from the National Academy of Neuropsychology, Early Career
Award from the American Society for Clinical Psychopharmacology,
Wechsler Early Career Award for Innovative Research on Cognition
from the American Psychological Foundation, and Young Investigator
Awards from the International Congress on Schizophrenia Research
and the Schizophrenia International Research Society. He has
received over $15M in grants as Principal Investigator or
Co-Investigator from the NIMH, NARSAD, VA MIRECC, APF, NSF and
G-PREP. He serves on the editorial boards of Schizophrenia
Bulletin, Journal of Abnormal Psychology, Clinical Psychological
Science, and Schizophrenia Research: Cognition.
Philip D. Harvey, PhD is Leonard M. Miller Professor of
Psychiatry and director of the Division of Psychology at the
University of Miami Miller School of Medicine and a VA Senior
Health Scientist. Dr. Harvey’s research has focused on cognition
and functioning, and he has written extensively on aging in
schizophrenia, negative symptoms in schizophrenia, functional
impairments in severe mental illness, the cognitive effects of
typical and atypical antipsychotics, and the effects of cognitive
enhancing agents and cognitive training in various conditions. He
is the author of over 1,000 scientific papers and abstracts, and he
has written over 60 book chapters. Dr. Harvey is a widely cited
author who was repeatedly designated by Thompson-Reuters as being
in the top 1% of all researchers in citations in mental health each
year since 2010. He has received numerous awards for his research
in schizophrenia.
This event is intended for institutional investors, sell-side
analysts, investment bankers, and business development
professionals only. Please RSVP in advance if you plan to attend,
as space is limited. Members of the media and the public are
invited to participate via the live webcast.
About Minerva Neurosciences
Minerva’s proprietary compounds include: roluperidone (MIN-101),
in clinical development for schizophrenia; seltorexant (MIN-202 or
JNJ-42847922), in clinical development for insomnia and MDD; and
MIN-301, in pre-clinical development for Parkinson’s disease.
Minerva’s common stock is listed on the NASDAQ Global Market under
the symbol “NERV.” For more information, please visit
www.minervaneurosciences.com.
Forward-Looking Safe Harbor Statement
This press release contains forward-looking statements which are
subject to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995, as amended. Forward-looking
statements are statements that are not historical facts, reflect
management’s expectations as of the date of this press release, and
involve certain risks and uncertainties. Forward-looking statements
include statements herein with respect to the timing and scope of
future clinical trials and results of clinical trials with
roluperidone (MIN-101); the clinical and therapeutic potential of
this compound; the timing and outcomes of future interactions with
U.S. and foreign regulatory bodies; our ability to successfully
develop and commercialize our therapeutic products; the sufficiency
of our current cash position to fund our operations; and
management’s ability to successfully achieve its goals. These
forward-looking statements are based on our current expectations
and may differ materially from actual results due to a variety of
factors including, without limitation, whether roluperidone will
advance further in the clinical trials process and whether and
when, if at all, it will receive final approval from the U.S. Food
and Drug Administration or equivalent foreign regulatory agencies
and for which indications; whether any of our therapeutic products
will be successfully marketed if approved; whether any of our
therapeutic product discovery and development efforts will be
successful; management’s ability to successfully achieve its goals;
our ability to raise additional capital to fund our operations on
terms acceptable to us; and general economic conditions. These and
other potential risks and uncertainties that could cause actual
results to differ from the results predicted are more fully
detailed under the caption “Risk Factors” in our filings with the
Securities and Exchange Commission, including our Quarterly Report
on Form 10-Q for the quarter ended September 30, 2019, filed
with the Securities and Exchange Commission on November 4,
2019. Copies of reports filed with the SEC are posted on
our website at www.minervaneurosciences.com. The forward-looking
statements in this press release are based on information available
to us as of the date hereof, and we disclaim any obligation to
update any forward-looking statements, except as required by
law.
Contact:
William B. BoniVP, Investor Relations/Corp.
CommunicationsMinerva Neurosciences, Inc.(617) 600-7376
Minerva Neurosciences (NASDAQ:NERV)
Historical Stock Chart
From Apr 2024 to May 2024
Minerva Neurosciences (NASDAQ:NERV)
Historical Stock Chart
From May 2023 to May 2024